# A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Source: https://onco.cc/trials/nct06090539/  
OnCo record `nct06090539` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rituximab, Glofitamab, Obinutuzumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Bristol-Myers Squibb, now recruiting.

## Summary

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas is a phase 1/2 interventional study registered as NCT06090539 by Bristol-Myers Squibb, with 460 participants planned, started 2023-12-29 and due to reach its primary completion in 2027-10-28. Interventions recorded: BMS-986458, Rituximab, Glofitamab/Obinutuzumab, Mosunetuzumab, Epcoritamab. Conditions listed: Relapsed/Refractory Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06090539
- Phase: 1/2
- Setting: A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Sponsor: Bristol-Myers Squibb
- Enrolled: 460

## Sources

- ClinicalTrials.gov NCT06090539: https://clinicaltrials.gov/study/NCT06090539

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Glofitamab](https://onco.cc/drugs/glofitamab/), [Golcadomide](https://onco.cc/drugs/golcadomide/), [Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct06090539.json